Key Takeaways IQVIA beat Q4 earnings and revenue estimates, delivering 9.6% EPS growth and 10.3% Y/Y revenue rise.IQV posted segment gains: R&D and Technology & Analytics grew about 10%, while Contract Sales surged 18.6%.IQVIA guided 2026 revenues at $17.15-$17.35B and reported $2B cash with $561M in Q4 free cash flow.IQVIA Holdings Analytics Inc. (IQV) has reported impressive fourth-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings were $3.42 per share, ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - Senior VP of Investor Relations and TreasuryMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Resear ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - VP of Investor RelationsMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Research AnalystJustin Bow ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Speaker7Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would ...

IQVIA Holdings (IQV) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.4 per share. This compares to earnings of $3.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.50%. A quarter ago, it was expected that this clinical testing company would post earnings of $2.96 per share when it actually produced earnings of $3, delivering a surprise of +1.35%.Over the last four quarters, t ...

Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re... ...

Q4 2025 Earnings Call February 5, 2026 © 2026. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. IQVIA Template (V4.0.0) 100% 50% 75% 25% Bright Blue Indigo Bright Teal Bright Green Emerald 5% Charcoal Red Legal 2 IQVIA Template (V2.1.0) 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q4 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "fo ...

Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance RESEARCH TRIANGLE PARK, N.C. – February 5, 2026 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025. "IQVIA closed 2025 with strong performance across all segments," said Ari Bousbib, chairman ...

Key Takeaways IQV is set to report Q4 results on Feb. 5, with revenues expected at $4.2B and EPS of $3.40, up 9% y/y.IQV TAS and R&D units will likely rise 6.9% and 7.7%, respectively, on drug launches and a solid RFP pipeline.IQV's geographic growth outlook indicates y/y Asia-Pacific revenue growth of 9.4% to $882.6M.IQVIA Holdings Inc. (IQV) is set to release fourth-quarter 2025 results on Feb. 5, before market open.IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate ...

白皮书 欧洲生物类似药竞争的影响 2026年1月 MAX 牛顿, 总裁，全球战略合作伙伴，IQVIA 凯莉·斯托达特， 资深顾问，全球供应商与协会关系，IQVIA 奥雷利奥·阿里亚斯 全球思想领袖总监，艾昆纬 目录 引言1 | IQVIA观察 | 2 | | --- | --- | | 1. 管道 | 4 | | 2. 商业吸引力 | 6 | | 3. 国际竞争力 | 9 | | 4. 获取不平等 | 10 | | 5. 高级计划 | 14 | | 方法论 | 16 | | 国家和产品细分KPI | 18 | | 粒细胞集落刺激因子 (GCSF) | 18 | | 抗肿瘤坏死因子（抗TNF） | 20 | | 胰岛素22 | | | 肿瘤学 | 24 | | 甲状旁腺激素（特立帕肽） | 26 | | 眼科 28 | | | 附录 | 30 | | EMA批准的生物类似药清单 | 30 | | ema 审批中的生物类似药列表 | 36 | | 参考文献 | 37 | 关于作者 38 了解更多 39 引言 欧洲生物类似药竞争影响报告第11版在去年的出版物观点的基础上构建，并提供了对欧 洲生物类似药竞争即将到来的 ...